Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | IDO1 | P14902 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591102 | 0.81 | GAA (0.64) | PKMMEN1KMT2AIDO1LMNA | |
| SCHEMBL489909 | 0.81 | PKM (0.61) | PKMMEN1KMT2AIDO1LMNA | |
| SCHEMBL14333569 | 0.81 | GAA (0.60) | PKMMEN1KMT2AIDO1LMNA | |
| SCHEMBL5637766 | 0.75 | TRIM24 (0.76) | PKMIDO1LMNAALDH1A1TRIM24 | |
| SCHEMBL23055895 | 0.74 | TRIM24 (0.54) | PKMMEN1KMT2AIDO1LMNA | |
| SCHEMBL10153730 | 0.72 | PDE3B (0.45) | PKMMEN1KMT2APOLB | |
| SCHEMBL9931338 | 0.72 | CCR2 (0.64) | PKMMEN1KMT2ALMNAPOLB | |
| SCHEMBL3984892 | 0.72 | PNMT (0.57) | PKMMEN1KMT2ALMNAGAA | |
| SCHEMBL434054 | 0.72 | TRIM24 (0.54) | PKMMEN1KMT2AIDO1LMNA | |
| SCHEMBL30222138 | 0.72 | TRIM24 (0.54) | PKMMEN1KMT2AIDO1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | PKM 4499/4885MEN1 4630/4885KMT2A 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.